Gapping down
In reaction to strong earnings/guidance:
- NA.
Other news:
- CBIO -42.6% (provides update on the ongoing Phase 1/2 trial investigating its next generation Factor IX candidate CB 2679d/ISU304 for the treatment of severe hemophilia B)
- ZIOP -11.6% (FDA placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in support of the IND application for the trial)
- TRVN -2.9% (entered into $50 mln at the market issuance Common Stock Sales Agreement with Cowen; also files for $175 mln mixed securities shelf offering)
- ALV -2.4% (priced a 5-year bond offering of EUR 500 mln in the Eurobond market)
- GLMD -2.3% (to offer and sell ordinary shares in an underwritten public offering to raise aggregate proceeds of approximately $75 mln), .
Analyst comments:
- RDFN -4.7% (downgraded to Sell from Neutral at Goldman)
- ZG -2.8% (downgraded to Neutral from Buy at Goldman)
- LDOS -1.7% (downgraded to Neutral from Buy at Goldman)
- INTC -1.7% (downgraded to Under Perform from Market Perform at Northland Capital)
- DISCA -1.5% (downgraded to Hold at Pivotal Research Group)
- DIS -0.9% (downgraded to Sell at Pivotal Research Group)
- CB -0.9% (downgraded to Neutral from Buy at Goldman)
![]()